Remove Drug Development Remove Immunity Remove White Paper
article thumbnail

Alzheimer’s disease biomarkers galvanise rocky drug development space

Pharmaceutical Technology

A Phase II study of the pharmacodynamic effects of semorinemab (RG 6100), an investigational drug being developed by Roche and AC Immune, on plasma and cerebrospinal fluid (CSF) also took into account plasma and CSF p-tau levels to determine individuals’ response to treatment. Please check your email to download the Report.

article thumbnail

Alzheimer’s disease biomarkers galvanize rocky drug development space

Pharmaceutical Technology

A Phase II study of the pharmacodynamic effects of semorinemab (RG 6100), an investigational drug being developed by Roche and AC Immune, on plasma and cerebrospinal fluid (CSF) also took into account plasma and CSF p-tau levels to determine individuals’ response to treatment. Please check your email to download the Report.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Eucure Biopharma and Chipscreen NewWay sign licence deal for YH008

Pharmaceutical Technology

Biocytogen’s independently developed bispecific antibody, YH008, exerts antagonistic and agonistic activities. It was engineered with an Fc-silent IgG1 isotype to avoid activation of Fc-receptor-mediated non-specific immune. It also activated tumour-infiltrating DCs and T cells in vivo pharmacodynamic studies.

article thumbnail

UCB and Cancer Research UK partner for oncology antibody candidates

Pharmaceutical Technology

UCB4594 targets the immune checkpoint, human leukocyte antigen G, which is also called HLA-G. Under the partnership, the Centre for Drug Development of Cancer Research UK will appoint the chief clinical and scientific investigators.

article thumbnail

Race to the finish: pharma edges closer to approval with RSV vaccines

Pharmaceutical Technology

Pharmaceutical companies are pushing to develop drugs and vaccines for RSV with these populations in mind. Since the FDA approved AstraZeneca’s monoclonal antibody therapy Synagis (palivizumab) 25 years ago, drug development successes for RSV have been few and far between.

article thumbnail

Pharma Fix: The quest for the next tuberculosis vaccine

Pharmaceutical Technology

In light of World TB day on March 24, the field hopes to overcome some major barriers to the drug development landscape. Unfortunately, lack of funding and resources remain an obstacle within the TB field for developing new vaccines. The BCG vaccine is a live-attenuated virus vaccine.

article thumbnail

FDA Commissioner envisions fewer delays, more clinical trial flexibility and AI use

Pharmaceutical Technology

Reports Use of Artificial Intelligence in Pharmaceutical Drug Development a. fired 17 sitting members of the Advisory Committee on Immunization Practices at the Centers for Disease Control and Prevention (CDC), concerns rose about the stance of federal agencies on vaccines. Find out more Sign up for our daily news round-up!